Radiopharmaceuticals & Theranostics
The modality reshaping the next decade of radiation oncology.
Who we work with
- Health systems
- Operating cancer centers
- Investors in radiopharma platforms
- Strategic acquirers
Radiopharmaceuticals and theranostics are reshaping how radiation oncology programs think about access, supply, and patient flow. We help operators and investors integrate these therapies without breaking the rest of the service line.
Radioligand therapies introduce supply-chain, scheduling, and reimbursement dynamics that a traditional radiation oncology program is not built to absorb. Done well, they expand the franchise. Done poorly, they create operational drag and capital risk.
We work with leadership teams on the program design, partnerships, and site-readiness questions that determine whether a theranostics build expands the program or strands capital.
Where we focus
- Theranostics program design and integration
- Isotope supply, partnerships, and logistics
- Site readiness for emerging radioligand therapies
- Operational integration with existing radiation oncology service lines
- Strategic and commercial diligence on radiopharma platforms
Where the rest of the radiation oncology landscape sits.
Most engagements start with a single, focused conversation.
Tell us where the situation is, and we'll tell you whether we're the right firm for it.